Am J Physiol Heart Circ Physiol 304: H916–H926, 2013.
First published February 1, 2013; doi:10.1152/ajpheart.00026.2012.
CALL FOR PAPERS
Mitochondria in Cardiovascular Physiology and Disease
Glutathione oxidation unmasks proarrhythmic vulnerability of chronically
hyperglycemic guinea pigs
Chaoqin Xie,1 Nora Biary,1 Carlo G. Tocchetti,2 Miguel A. Aon,2 Nazareno Paolocci,2 Justin Kauffman,1
and Fadi G. Akar1
1
Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York; and 2Division of Cardiology, Johns
Hopkins University, Baltimore, Maryland
Submitted 12 January 2012; accepted in final form 25 January 2013
Xie C, Biary N, Tocchetti CG, Aon MA, Paolocci N, Kauffman J,
Akar FG. Glutathione oxidation unmasks proarrhythmic vulnerability of
chronically hyperglycemic guinea pigs. Am J Physiol Heart Circ Physiol
304: H916 –H926, 2013. First published February 1, 2013;
doi:10.1152/ajpheart.00026.2012.—Chronic hyperglycemia in type-1
diabetes mellitus is associated with oxidative stress (OS) and sudden
death. Mechanistic links remain unclear. We investigated changes in
electrophysiological (EP) properties in a model of chronic hyperglycemia before and after challenge with OS by GSH oxidation and
tested reversibility of EP remodeling by insulin. Guinea pigs survived
for 1 mo following streptozotocin (STZ) or saline (sham) injection. A
treatment group received daily insulin for 2 wk to reverse STZinduced hyperglycemia (STZ ⫹ Ins). EP properties were measured
using high-resolution optical action potential mapping before and
after challenge of hearts with diamide. Despite elevation of glucose
levels in STZ compared with sham-operated (P ⫽ 0.004) and STZ ⫹
Ins (P ⫽ 0.002) animals, average action potential duration (APD) and
arrhythmia propensity were not altered at baseline. Diamide promoted
early (⬍10 min) formation of arrhythmic triggers reflected by a higher
arrhythmia scoring index in STZ (P ⫽ 0.045) and STZ ⫹ Ins (P ⫽
0.033) hearts compared with sham-operated hearts. APD heterogeneity underwent a more pronounced increase in response to diamide in
STZ and STZ ⫹ Ins hearts compared with sham-operated hearts.
Within 30 min, diamide resulted in spontaneous incidence of ventricular tachycardia and ventricular fibrillation (VT/VF) in 3/6, 2/5, 1/5,
and 0/4 STZ, STZ ⫹ Ins, sham-operated, and normal hearts, respectively. Hearts prone to VT/VF exhibited greater APD heterogeneity
(P ⫽ 0.010) compared with their VT/VF-free counterparts. Finally,
altered EP properties in STZ were not rescued by insulin. In conclusion, GSH oxidation enhances APD heterogeneity and increases
arrhythmia scoring index in a guinea pig model of chronic hyperglycemia. Despite normalization of glycemic levels by insulin, these
proarrhythmic properties are not reversed, suggesting the importance
of targeting antioxidant defenses for arrhythmia suppression.
type-1 diabetes mellitus; insulin; oxidative stress; electrical remodeling; conduction; repolarization; arrhythmias
PATIENTS WITH type-1 diabetes mellitus (t1DM) are at a heightened risk of sudden cardiac death (29). Increased mortality in
these patients is attributable to a variety of cardiovascular
complications including atherosclerosis, ischemic injury, and
myocardial infarction, all of which are important risk factors
for ventricular arrhythmias (8). Growing evidence implicates
oxidative stress (OS) in general and glutathione (GSH) deple-
Address for reprint requests and other correspondence: F. G. Akar, Cardiovascular Inst., Mount Sinai School of Medicine, 1 Gustave L. Levy Pl., New
York, NY 10029 (e-mail: fadi.akar@mssm.edu).
H916
tion, in particular in the pathophysiology of t1DM (13a, 25a,
34, 42). Whether OS is a required component of the arrhythmia
substrate of the diabetic heart is unknown.
Previous studies of arrhythmia mechanisms in t1DM hearts
have extensively focused on ion channel remodeling at the
isolated myocyte level (25, 40, 45, 46). Several studies identified prolongation of the action potential duration (APD) as an
important electrophysiological (EP) signature of myocytes
from diabetic hearts (25, 46). Because APD and QT-interval
prolongation promote early afterdepolarization-mediated triggers and polymorphic ventricular tachycardia and ventricular
fibrillation (VT/VF) in acquired and congenital forms of the
long QT syndrome and heart failure, it was proposed that APD
prolongation in t1DM may also be arrhythmogenic. In support
of this idea is the fact that QT-interval prolongation has
emerged as an important risk factor for mortality in patients
with t1DM (11).
On the other hand, cellular EP studies in t1DM were mostly
performed in small rodents (mice and rats) whose AP profile
lacks a plateau phase and whose rapid repolarization kinetics
are governed almost exclusively by the transient outward K⫹
current (Ito) (6, 19, 26, 31, 38 – 40, 46). In contrast, guinea pigs
and larger mammalian species, including humans, exhibit action potentials that have a prominent plateau phase and that
display gradual repolarization kinetics that are not strictly
dependent on Ito. Rather, terminal repolarization and APD in
these species reflect a delicate balance in the activation and
inactivation properties of multiple ionic currents, including the
delayed rectifier K⫹ currents, the sodium-calcium exchanger,
the L-type calcium current, and the inward rectifier K⫹ current.
This distinction is important because unlike rodents, patients
with t1DM do not exhibit heart rate corrected QT-interval
prolongation in the absence of confounding factors, such as
diabetic ketoacidosis (24) or spontaneous hypoglycemia (11).
Clinically, these additional stimuli are required to unmask
pathological QT-interval prolongation in patients with t1DM
(11, 14, 17, 24).
More importantly, most EP studies in t1DM have been
performed in animal models that exhibited highly artificial
rises (⬎300%) in blood glucose levels that are well beyond
what is commonly encountered in patients with diabetes (20,
33, 36, 40, 46). Such extreme levels of hyperglycemia, which
are known to affect ion channels, preclude the direct translation
of some of these earlier findings to humans. Therefore, a major
objective of the present study was to create a robust and
reproducible animal model of chronic hyperglycemia that ex-
0363-6135/13 Copyright © 2013 the American Physiological Society
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
http://www.ajpheart.org
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
hibits qualitatively similar elevations in plasma glucose levels,
as found in humans (i.e., by ⬃25–50%), and in which EP
properties could be related directly to arrhythmia propensity.
Specifically, we performed a comprehensive investigation of
the tissue-level EP substrate in a guinea pig model of streptozotocin (STZ)-induced hyperglycemia and investigated for the
first time the potential reversibility of EP remodeling by
chronic insulin treatment. Finally, because GSH depletion is
central to the pathophysiology of t1DM (13a, 25a, 34, 42), we
hypothesized that GSH oxidation using diamide may unmask
functionally important differences in EP properties and promote arrhythmias in chronic hyperglycemia.
METHODS
Experimental Models of Chronic Hyperglycemia With and Without
Chronic Insulin Treatment
Procedures involving the handling of animals were approved by the
Animal Care and Use Committee and adhered with the Guide for the
Care and Use of Laboratory Animals, published by the National
Institutes of Health (NIH publication No. 85-23, Revised 1996).
Experimental models of chronic hyperglycemia with and without
insulin treatment were prepared at Hilltop Lab Animals (Scottdale,
PA) according to a protocol designed for this study (Fig. 1A). Briefly,
adult male Hartley guinea pigs were allowed to survive for 1 mo
following a single intraperitoneal injection (80 mg/kg in citrate buffer)
of buffered STZ (n ⫽ 11) or an equivalent volume of citrate-buffered
saline (sham, n ⫽ 10). A treatment group (n ⫽ 6) received 1 U/day
insulin glargine (Lantus, Aventis) by subcutaneous injection for an
additional 2 wk following onset of hyperglycemia by STZ injection
(STZ ⫹ Ins). A group of eight normal guinea pigs was used to
establish the protocol of acute OS by diamide perfusion (Fig. 1, B and
H917
C). Before animal death, blood glucose levels were measured three to
five times per animal using the clarity plus glucometer (Diagnostic
Test Group, Boca Raton, FL). The in vivo protocol used to induce
hyperglycemia resulted in a significant elevation in plasma glucose
levels, which is comparable (on a percent basis) with what is observed
in patients with t1DM (Fig. 2A).
Ex Vivo Optical Action Potential Mapping
Following assessment of plasma glucose levels, guinea pigs (n ⫽
26) were anesthetized and their hearts were rapidly excised and
retrogradely perfused via the aorta with oxygenized (95% O2-5%
CO2) Tyrode solution containing (in mM) 130 NaCl, 1.2 MgSO4, 25
NaHCO3, 4.75 KCl, 5 dextrose, and 1.25 CaCl2 at 36.5 ⫾ 1°C. Both
atria were surgically removed to avoid competitive stimulation of the
ventricles by the sinoatrial node. Perfusion pressure was maintained at
⬃60 –70 mmHg by adjusting the perfusion flow rate.
Hearts were positioned in a custom-built chamber with their anterior surface gently pressed against a glass imaging window by a
customized U-shaped piston, as described in detail elsewhere (21, 28).
Movement was suppressed using 10 M blebbistatin (Tocris Bioscience) mixed in Tyrode solution for 10 min. Preparations were immersed in the coronary effluent to maintain temperature at 36 ⫾ 1°C.
Volume-conducted electrocardiograms (ECG) were recorded for cardiac rhythm monitoring, analysis, and arrhythmia scoring using noncontact silver electrodes. ECG signals were amplified using the
ECG100-MP150 amplifier system and the Acqknowledge 3.9 software
package (Biopac System, Goleta, CA).
After stabilizing for 10 min, hearts were stained with 20 M of the
voltage-sensitive dye di-4-ANEPPS (Invitrogen) mixed in Tyrode solution for 10 min. Hearts were excited with filtered light (515 ⫾ 5 nm) from
a high-power, low-noise quartz tungsten halogen lamp (Newport, CT).
The emitted fluorescence was filtered (⬎620 nm) and focused onto a
high-resolution, 80 ⫻ 80-pixel CCD camera (SciMeasure) that was
Fig. 1. In vivo and ex vivo experimental
models and protocols. A: development of
guinea pig models of streptozotocin-induced
hyperglycemia with (STZ ⫹ Ins) and without
(STZ) chronic insulin treatment. B: ex vivo
experimental protocols used to determine
electrophysiological properties. C: Diamideinduced changes in mitochondrial and electrical properties in normal guinea pig hearts,
indicating stable membrane potential (⌬⌿m;
left) and action potential (right) properties
during the initial 30-min period of challenge.
These measurements guided the ex vivo electrophysiological protocol used in sham-operated, STZ, and STZ ⫹ Ins groups, in which
we focused on this 30-min window. APD,
action potential duration; VT/VF, ventricular
tachycardia and ventricular fibrillation; ASI,
arrhythmia scoring index.
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
H918
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
A
B
300
Blood Glucose
P=0.002
PCL (ms) 200
C
200
100
0
250
Protocol 1
mg/dl
P=0.004
Normoxic Perfusion
5mm
Sham
STZ
STZ
+Ins
300
350
400
450
500
S2 (ms)
S1=300ms
S2
280
D
Protocol 2
260
240
220
200
180
160
1s
Diamide Challenge
Protocol 3
E
PCL=300ms
Baseline
Diamide
1s
Fig. 2. Animal models of STZ ⫹ Ins and STZ. A: average blood glucose levels in sham-operated (saline injected), STZ, and STZ ⫹ Ins animals. B: ex vivo
perfused guinea pig heart indicating approximate location and size of the mapping field on the left ventricular epicardium. Also shown are representative
simultaneously recorded action potentials from across the 4 ⫻ 4-mm2 region. C and D: ex vivo experimental protocols. C: protocol 1, representative volume
conducted ECG traces recorded during steady-state pacing at a wide range of pacing cycle lengths (PCLs; 200 –500 ms). D: protocol 2, programmed electrical
stimulation using a single premature extra-stimulus delivered at decreasing coupling intervals until arrhythmias were produced or refractoriness encountered.
E: protocol 3, arrhythmia propensity by challenge with oxidative stress produced by GSH oxidation (perfusion with 200 M diamide).
coupled to an imaging macroscope containing a modular high-numerical
aperture lens, a dichroic mirror, excitation and emission filters, a beam
splitter, and a light collimating tube.
During each recording, 6,400 independent action potentials were
simultaneously imaged from a 4 ⫻ 4-mm2 region of the left ventricular (LV) epicardium (Fig. 2B) yielding an inter-pixel resolution of 50
m ⫻ 50 m. To further improve signal quality, a 4 ⫻ 4 digital
binning filter was applied to the raw signals, thereby reducing the
effective spatial resolution to 200 m ⫻ 200 m. As illustrated in Fig.
1B, this strategy allowed the accurate detection of activation and
repolarization times from all action potentials across the mapping field
(Fig. 2B).
Ex Vivo Experimental Protocols
Normoxic perfusion. Each heart was subjected to an identical set of
experimental protocols (Fig. 1B). Initially, hearts were perfused with
normal Tyrode solution. Following assessment of baseline EP properties, hearts were paced at multiple cycle lengths ranging from 200 to
500 ms, as illustrated in Fig. 2. Using this protocol, we investigated
the rate dependence of EP properties in hearts from sham-operated,
STZ, and STZ ⫹ Ins animals.
Hearts were then challenged with an ex vivo programmed electrical
stimulation (PES) protocol, which entailed delivery of premature
impulses (S2) at decreasing coupling intervals (in 20-ms decrements)
relative to the pacing (S1) train (cycle length, 300 ms) until refractoriness was encountered or an arrhythmia induced (Fig. 2D). APD
restitution defined as the APD dependence of the premature (S2) beat
on the previous S1S2 coupling interval was assessed. Stimuli were
delivered using a silver electrode placed on the anterior LV surface
(Fig. 2B). The stimulus strength was set to two times the diastolic
pacing threshold at a pulse width of 2 ms.
Diamide perfusion. Since none of the hearts exhibited arrhythmias
during normoxic perfusion (see Results), hearts were challenged with
a reliable ex vivo protocol of OS by diamide (200 M) perfusion,
which produces mitochondrial and electrical dysfunction (9). We
focused on the initial 30-min period of diamide perfusion, because in
preliminary experiments, we found that normal hearts remained electrically and metabolically stable during that time course (Fig. 1C).
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
Sensitivity to OS challenge was quantified in sham-operated, STZ,
and STZ ⫹ Ins hearts upon early (10 min) exposure to diamide using
an arrhythmia scoring index (ASI), which reflects the presence and
severity of arrhythmic triggers. Detailed measurements of APD heterogeneity across the mapping field were performed for paced beats
following 10 min of diamide perfusion in all hearts (early challenge).
Diamide perfusion was sustained for 30 min in all hearts to assess
the spontaneous induction rate of VT/VF. Measurements of APD
heterogeneity were repeated for paced beats following 30 min of
diamide challenge in VT/VF (⫺) hearts or during the last minute of
successful pacing before onset of arrhythmias in VT/VF (⫹) hearts.
This allowed us to compare APD heterogeneity in VT/VF (⫺) versus
VT/VF (⫹) hearts. Although guinea pig preparations are stable for
over 4 h of ex vivo perfusion, all experimental protocols were
completed within 2.5 h of animal death.
EP Measurements
Action potential duration. APD was defined as the difference
between repolarization and activation times for each recorded action
potential. Activation time was defined as the maximum first derivative
during the action potential upstroke, whereas repolarization time was
defined as the point of maximum second derivative during the repolarization phase at each site. APD values were measured during
steady-state pacing before and after challenge with diamide and
immediately (within 1 min) before onset of spontaneous arrhythmias.
APD heterogeneity. APD heterogeneity was quantified as the standard deviation (SD-APD) or range (R-APD) of APD values measured
over a 4 ⫻ 4-mm2 region of the LV epicardium. SD-APD and R-APD
were measured in all hearts during steady-state pacing before and after
challenge with diamide. APD heterogeneity was first measured following 10 min of diamide treatment. APD heterogeneity was also
measured before spontaneous onset of arrhythmias by diamide in
VT/VF (⫹) hearts or at the end of the 30-min diamide protocol in
VT/VF (⫺) hearts.
Conduction velocity. Velocity vectors (magnitude and direction)
were derived from the activation times of each pixel relative to those
of its neighbors. Conduction velocity (CV) was measured by averaging the magnitude of the velocity vectors along the main direction of
impulse propagation.
Arrhythmia scoring index. Arrhythmia sensitivity was evaluated by
using a standard ASI as we and others have previously described (7,
9, 22). Briefly, ASI was generated according to the following criteria
during the initial 10-min period of diamide challenge in each heart: 0,
0 ventricular premature beats; 1, 1–10 ventricular premature beats; 2,
11–50 ventricular premature beats; 3, 51–100 ventricular premature
beats; 4, 101–500 ventricular premature beats; 5, sustained VT/VF.
Statistical Analyses
EP differences between the sham-operated and experimental (STZ
or STZ ⫹ Ins) groups were compared using one-way ANOVA with
Tukey’s post hoc analysis in SPSS. Differences were considered
significant for P ⬍ 0.05. Student’s t-test was used to compare
differences in APD heterogeneity between VT/VF (⫹) and VT/VF
(⫺) hearts.
RESULTS
A New Model of Chronic Hyperglycemia in Guinea Pigs
Shown in Fig. 2A are average blood glucose levels in
sham-operated, STZ, and STZ ⫹ Ins animals before death.
Clearly, STZ injection produced a significant elevation (by
33.9%, P ⬍ 0.004) in plasma glucose levels compared with
saline-injected controls (sham). Importantly, hyperglycemia
in this guinea pig model was completely reversed by a 2-wk
regimen of daily insulin treatment (Fig. 2A, blue). Indeed,
H919
blood glucose levels were comparable [P ⫽ not significant
(NS)] between STZ ⫹ Ins and sham-operated animals.
Following assessment of in vivo blood glucose levels in all
groups, animals were euthanized and hearts rapidly excised,
cannulated, perfused, and stained for optical action potential
mapping studies (Fig. 2B). A detailed assessment of the EP
substrate and risk of arrhythmias was performed during
challenge with various ex vivo experimental protocols (Fig.
2, C–E).
Rate Dependence of APD
Several studies have reported APD prolongation in rat models of diabetes mellitus (47). Since most of these studies were
performed in isolated myocytes, the relevance of cellular APD
prolongation to arrhythmia propensity in the intact heart remained untested. By and large, these measurements were also
performed in models that exhibited excessive (⬎350%) elevations in plasma glucose levels that are well beyond what is
typically observed in patients with t1DM (i.e., ⬃25–50%) (13,
20, 33, 46). Therefore, we began by examining whether APD
prolongation is indeed a characteristic of this guinea pig model
which exhibits a qualitatively similar rise (on a percent basis)
in blood glucose levels, as clinically observed in patients.
Shown in Fig. 3A are average APD measurements obtained
over a wide range (200 –500 ms) of pacing cycle lengths in
sham-operated (black), STZ (red), and STZ ⫹ Ins (blue)
hearts. Also shown are representative action potential traces
recorded at multiple pacing cycle lengths from each group
(Fig. 3B). Surprisingly, we found no evidence of APD prolongation in this guinea pig model of STZ-induced chronic hyperglycemia, since average APD was virtually identical (P ⫽
NS) across groups at all pacing cycle lengths that were tested
(Fig. 3).
Conduction Remodeling
We proceeded to investigate potential differences in conduction properties. Shown in Fig. 4 are representative depolarization isochrone maps recorded from sham-operated, STZ, and
STZ ⫹ Ins hearts (Fig. 4A) and action potential upstrokes
depicting epicardial conduction delays caused by point stimulation in these hearts (Fig. 4B). Also shown are average
epicardial conduction velocities (Fig. 4C) and normalized upstroke velocity measurements (Fig. 4D). Clearly, CV underwent a modest (14.4%, P ⫽ 0.048) reduction in STZ compared
with sham-operated hearts. Interestingly, insulin treatment
failed to restore CV in STZ ⫹ Ins hearts to sham-operated
heart values despite complete normalization of blood glucose
levels. We next tested whether impaired conduction in chronic
hyperglycemia was caused by reduced excitability. As shown
in Fig. 4D, CV slowing could not be explained by a change in
excitability since the average normalized upstroke velocities
were not altered in STZ (P ⫽ NS) and STZ ⫹ Ins (P ⫽ NS)
hearts compared with sham-operated hearts.
Arrhythmia Propensity During Baseline Perfusion
Previous studies in rodents suggested (but did not demonstrate) that EP changes; namely, APD prolongation and conduction slowing may underlie an increased susceptibility of the
t1DM heart to arrhythmias. Therefore, we began by asking
whether hearts from STZ-injected guinea pigs were indeed
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
H920
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
Fig. 3. Rate-dependence of APD at the tissue
level. A: average rate dependence of APD in
sham-operated (black), STZ (red), and Instreated (blue) animals. B: representative action potential traces recorded over a wide
range (200 –500 ms) of PCLs from each
group.
more vulnerable to the incidence of arrhythmias. To address
this question, we challenged hearts with an ex vivo PES
protocol (Fig. 2D) that we had previously used to uncover
heightened arrhythmia propensity in various animal models of
heart disease, including heart failure and the long QT syndrome (3, 5). As shown in Fig. 5A, PES failed to induce
arrhythmias in all groups during baseline perfusion. Moreover,
a plot of the S2 APD as a function of the preceding coupling
interval (S1S2) revealed similar APD restitution kinetics for
sham-operated, STZ, and STZ ⫹ Ins groups (Fig. 5, B and C).
Because challenge of STZ and STZ ⫹ Ins hearts with PES
failed to elicit arrhythmias, the relevance of altered EP properties remained unknown. We next hypothesized that GSH
oxidation using diamide may unmask otherwise subtle differences in arrhythmia susceptibility between groups and that this
strategy may identify functionally significant differences in EP
properties. To that end, hearts from sham-operated, STZ, and
STZ ⫹ Ins animals were challenged with 200 M diamide.
Importantly, the arrhythmic sensitivity of hearts could be
quantitatively compared between groups during predefined
early (10 min) and late (30 min) intervals of diamide exposure.
As shown in Fig. 6A, diamide challenge for 10 min revealed a
marked increase in ASI in STZ (P ⫽ 0.045) and STZ ⫹ Ins
(P ⫽ 0.033) hearts compared with sham-operated hearts. The
early rise in ASI was caused by enhanced ectopy as evidenced
by presence of spontaneous action potential wave fronts emanating from multiple foci (Fig. 6B). These data suggest that
chronically hyperglycemic animals (STZ group) are indeed
more sensitive to OS-mediated arrhythmia triggers compared
with controls (sham-operated group). In addition, we compared
the spontaneous incidence of sustained VT/VF within a 30-min
period of diamide perfusion. As shown in Figure 6C, there was
a trend (P ⫽ 0.13) toward a greater incidence of VT/VF in STZ
(3/6) compared with combined normal and sham-operated
animals (1/9). Importantly, insulin treatment (STZ ⫹ Ins
group) failed to reduce ASI (Fig. 6A, P ⫽ NS) and the
incidence of VT/VF (Fig. 6C) compared with STZ alone.
Diamide-Mediated EP Properties
We proceeded to investigate differences in the EP substrate
between groups during diamide challenge. Ex vivo perfusion
with diamide (200 M) caused a comparable decrease in
APD in all groups (Fig. 7A) before arrhythmia onset. Hence,
diamide-induced changes in average APD could not explain
inherent differences in arrhythmia vulnerability between
groups.
We next investigated potential differences in APD heterogeneity, a known mechanism of proarrhythmia in various
congenital and acquired cardiovascular disorders. Shown in
Fig. 7C are representative APD contour maps measured from
sham-operated, STZ, and STZ ⫹ Ins hearts at baseline and
following challenge with diamide for 10 min. Also shown are
the average SD-APD and R-APD across the mapping field in
all groups (Fig. 7D). STZ hearts were associated with significantly greater APD heterogeneity compared with sham-oper-
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
H921
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
Sham
A
STZ
STZ+Ins
Depolarization
11ms
0ms
1mm
B
10ms
C
10ms
Conduction Velocity
10ms
D
Normalized Upstroke Velocity
P=0.048
80
1
0.8
dF/F
cm/s
60
40
20
0.6
0.4
0.2
0
0
Sham
STZ
STZ + Ins
Sham
STZ
STZ + Ins
Fig. 4. Conduction remodeling in chronic hyperglycemia and its potential reversal by Ins. A: representative depolarization isochrone maps recorded from
sham-operated, STZ, and STZ ⫹ Ins hearts. B: representative first derivatives of the action potential upstroke recorded simultaneously from equidistant sites of
sham-operated, STZ, and STZ ⫹ Ins hearts, indicating conduction delay across the mapping field. C: average conduction velocity in all sham-operated (black),
STZ (red), and STZ ⫹ Ins (blue) hearts. D: average normalized upstroke velocity as an index of cellular excitability [maximum amplitude of first derivative
divided by the action potential amplitude (dF/F)] in sham-operated, STZ, and STZ ⫹ Ins hearts.
ated hearts. Interestingly, insulin treatment failed to restore
SD-APD and R-APD to sham-operated levels. While challenge
of hearts with diamide increased SD-APD in all groups, this
effect was significantly more pronounced in the STZ (by
39.2%) and STZ ⫹ Ins (by 43.7%) groups compared with their
sham-operated counterpart (by 24.3%). To further investigate
the functional relevance of increased APD heterogeneity, we
compared SD-APD and R-APD between hearts that were prone
to (⫹) versus protected against (⫺) sustained VT/VF within a
30 min window of diamide perfusion. Remarkably, both SDAPD (P ⫽ 0.005) and R-APD (P ⫽ 0.010) were significantly
higher in hearts prone to diamide-induced VT/VF (Fig. 8, A
and B) compared with VT/VF free hearts.
DISCUSSION
In the present work, we set out to investigate the EP
substrate in a model of STZ-induced chronic hyperglycemia
and relate it directly to arrhythmia propensity. A major objective was to determine the potential reversibility of key EP
changes by insulin treatment. Finally, we asked whether hyperglycemia per se is a necessary and sufficient requirement for
the genesis of arrhythmias or whether additional factors, such
as OS, are required to unmask inherent vulnerabilities. To do
so, we developed a guinea pig model of chronic hyperglycemia
in which plasma glucose elevation closely matched what is
observed in patients with t1DM.
Guinea Pig Model of Chronic Hyperglycemia
The vast majority of previous studies focusing on the
electrophysiology of t1DM have relied on rodent models
with rapid repolarization kinetics (6, 13, 16, 31, 33, 39 – 41)
and/or in which highly artificial rises in blood glucose levels
were achieved (25, 47). In these earlier studies, APD prolongation was documented, leading to the speculation that
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
H922
A
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
S2 (ms)S1=300ms
280
S2
B
Sham
260
S2
280
240
260
220
200
240
STZ
180
160
S2 (ms)S1=300ms
280
S2
220
200
260
STZ
S1=300ms
S2(ms)
180
240
220
100ms
160
200
C
180
200
Sham
160
S2 (ms)S1=300ms
280
S2
STZ + Ins
260
240
S2 APD (ms)
180
STZ
STZ+Ins
160
140
220
120
200
100
150
180
200
250
300
S1-S2 (ms)
160
Fig. 5. Programmed electrical stimulation and restitution kinetics. A: representative volume-conducted ECGs from each group during challenge with programmed
electrical stimulation revealing lack of arrhythmia inducibility. B: representative S1 and S2 action potential traces recorded before and after challenge with
programmed electrical stimulation, respectively. C: restitution curves revealing the dependence of the S2 APD on the preceding S1S2 coupling interval in all
hearts from all groups.
prolonged APD at the cellular level likely underlies QTinterval prolongation in t1DM. Since APD prolongation is a
well-established arrhythmia mechanism in various models
of congenital and acquired heart diseases, it was further
speculated that such prolongation may underlie an enhanced
susceptibility to sudden cardiac death in diabetes. A major
objective of the present study was to verify the potential
link between altered APD properties and arrhythmia propensity in a model of chronic hyperglycemia that exhibits a
comparable rise in plasma glucose levels, as found in
humans.
Surprisingly, we found that despite significant hyperglycemia, average and rate dependence of APD in guinea pigs were
not altered compared with saline-injected animals (Fig. 3).
Instead, hearts from STZ-injected guinea pigs were characterized by normal action potential morphologies and durations.
Many factors may contribute to this apparent discrepancy.
Clearly, the most obvious is the relative contribution of Ito to
action potential repolarization across species. In rats, repolarization kinetics are almost exclusively dictated by Ito. Of note,
Li et al. (26) have demonstrated strong redox regulation of Ito
remodeling in the diabetic heart. In addition, slowing of Ito
recovery from inactivation caused by a switch in the molecular component of Ito from Kv4.x to Kv1.4 channels has
been documented in t1DM (31). Indeed, these findings may
underlie the striking reduction in repolarization reserve of
diabetic rats but not guinea pigs. Whereas Ito is expressed in
humans, its contribution to terminal repolarization is relatively minimal. Indeed, our findings are qualitatively similar
to those of Lengyel et al. (25) who reported a minimal
(⬍9%) change of APD in a canine model of Alloxaninduced diabetes.
A major objective of our experimental design was the
generation of an animal model that exhibits clinically relevant
elevations in plasma glucose levels while avoiding other confounding factors such as LV dysfunction and cardiomyopathy.
Indeed, the level of hyperglycemia achieved in this guinea pig
model (⬃34%) was more akin to what is observed in humans
(25–50%) compared with that observed in previous studies
reporting marked APD prolongation.
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
H923
DIAMIDE CHALLENGE
Early Challenge: Arrhythmia Score
A
B
A
Arrhythmia Score
P=0.033
A
5
A
A
A
A
P=0.045
4
A A B CD
Sham
3
A
2
1
A
B
STZ
0
Sham
STZ
STZ+Ins
Late Challenge: Spontaneous VT/VF
C
60
(3/6)
(2/5)
(1/9)
40
%
20
0
Normal
Sham
STZ
C
D
Fig. 6. Enhanced susceptibility of STZ and
STZ ⫹ Ins hearts to oxidative stress. A: assessment of relative sensitivity to early diamide
challenge by quantification of a standard ASI
during the initial 10-min period of diamide
challenge. A marked rise in ASI was observed
during the 10-min diamide challenge protocol
in STZ and STZ ⫹ Ins hearts compared with
sham-operated hearts. B: representative action
potential traces and isopotential contour maps
recorded from sham-operated and STZ hearts
following early challenge with diamide, showing enhanced susceptibility of STZ hearts to
GSH oxidation. While early diamide challenge
failed to disrupt steady-state baseline pacing of
sham-operated hearts, it caused the generation
of triggered beats in STZ hearts. Color bars
indicate depolarized myocardium (red) and
resting membrane potential (blue). C: percentage of hearts in each group (normal, sham-operated, STZ, and STZ ⫹ Ins) undergoing sustained VT/VF during a 30-min challenge with
diamide perfusion. Normal animals were uninjected. Sham-operated animals were injected
with saline buffer.
STZ+Ins
Finally, we found that guinea pigs with chronic hyperglycemia exhibited a stable rhythm with no change in the QTinterval duration on volume-conducted ECG recordings (sham,
209 ⫾ 10; STZ, 208 ⫾ 17; and STZ ⫹ Ins, 209 ⫾ 15 ms).
While QT-interval prolongation in patients with t1DM is an
important risk factor for sudden death, it is typically uncovered
by confounding factors such as ketoacidosis or spontaneous
hypoglycemia, known to occur in these patients (37). As such,
our finding of preserved APD and QT-interval in the absence
of additional pathogenic factors is consistent with stable clinical electrocardiographic properties of patients with t1DM
under basal conditions (37).
Conduction Slowing in Chronic Hyperglycemia and its
Potential Reversal by Insulin
Conduction abnormalities underlie the initiation and maintenance of reentrant arrhythmias in common structural heart
diseases, including ischemia (23), myocardial infarction (44),
hypertrophy (21), and heart failure (4, 18, 35). Of interest,
Shimoni and colleagues (39) identified conduction changes in
hearts of STZ-injected rats. Specifically, they found compelling evidence of reduced conduction reserve in male but not
female diabetic rat hearts. These sex-dependent changes in
conduction were related to remodeling of the main ventricular
gap junction protein, Cx43 in t1DM. Despite these elegant
findings, the functional relevance of conduction slowing or
reduced conduction reserve in t1DM remained speculative
because arrhythmias were not directly provoked in these studies. Therefore, we sought to investigate whether conduction is
indeed compromised in this guinea pig model of chronic
hyperglycemia and whether it is causally related to arrhythmogenesis. Our finding of minor (⬍15%) conduction slowing in
STZ compared with sham-operated animals is qualitatively
similar to that of Nygren et al. (32) who documented the
presence of conduction abnormalities in diabetes. However, a
major new finding of the present report is the demonstration
that despite conduction slowing during baseline normoxic
perfusion of the heart, arrhythmia propensity was not altered
since challenge of these hearts with PES failed to provoke
arrhythmias (Fig. 5A). As such, we argue against, not for, a
functionally significant role of conduction changes in the
setting of chronic hyperglycemia.
Proarrhythmic Triggers and Substrate in Chronic
Hyperglycemia
Emerging evidence implicates mitochondrial dysfunction
and OS as central features of the diabetic heart (10). Recently,
we and others demonstrated strong mechanistic links between
mitochondrial dysfunction caused by OS and arrhythmias (1, 7,
9). Whether OS is a required component of the arrhythmia
substrate of the diabetic heart remained unknown.
A major finding of the present report is the surprisingly
preserved electrical phenotype of hyperglycemic hearts during
baseline perfusion. However, upon challenge of hearts with
diamide, we uncovered a preferential sensitivity of STZ-injected animals to arrhythmic triggers. Using this strategy, we
directly related changes in the EP substrate to the incidence of
arrhythmias in the same hearts. We found that diamide-mediated APD shortening was comparable across groups and therefore could not account for differences in arrhythmia vulnerability. Similarly, OS by GSH oxidation did not alter conduction
properties or the action potential upstroke before arrhythmia
onset (not shown). These findings indicate that exogenous OS
in diabetic hearts did not cause arrhythmias by reducing excitability (i.e., promoting “metabolic sink”) (1, 2). As such, our
current findings argue against surface ATP-sensitive K⫹ channel activation driven by mitochondrial membrane potential
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
H924
APD
Sham
STZ
B
STZ + Ins
STZ
200
STZ+Ins
150
100
50
Baseline
Diamide
Sham
250
APD (ms)
A
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
100ms
0
Baseline
APD Heterogeneity
D
Sham
STZ
STZ + Ins
(ms)
192
188
Baseline
184
180
176
APD standard
deviation
C
172
Diamide
P=0.029
4
3
P=0.001
2
1
0
baseline
168
164
P=0.012
160
(ms)
20
Diamide
154
150
146
142
APD Range
(ms)
162
158
Diamide
P=0.002
P=0.021
15
10
5
138
134
130
0
baseline
Diamide
1 mm
Fig. 7. Diamide-induced changes in APD and APD heterogeneity. A: representative action potential traces recorded before and after challenge with diamide (last
minute before onset of VT/VF) in sham-operated, STZ, and STZ ⫹ Ins hearts. B: average APD measured during baseline (left) and following diamide challenge
(right) in sham-operated (black), STZ (red), and STZ ⫹ Ins (blue) hearts. C: representative APD contour maps measured at baseline and following 10-min
challenge with diamide in sham-operated, STZ, and STZ ⫹ Ins hearts. D: average APD heterogeneity indexed by the standard deviation and range of APD values
measured across the mapping field before and after challenge with 200 M diamide perfusion.
(⌬⌿m) depolarization as a primary arrhythmia mechanism in
chronic hyperglycemia.
Instead, we find that diamide challenge of STZ hearts leads
to a marked increase in the spatial heterogeneity of APD (Fig.
7). The exact mechanism underlying this important EP feature
remains unknown. However, one may speculate that increased
heterogeneity of the mitochondrial ⌬⌿m upon diamide perfusion may underlie APD heterogeneities at a microscopic level
APD Heterogeneity
VF(+) versus VF(-) hearts
A
4
P=0.005
VT/VF (-)
VT/VF (+)
3
2
1
0
Baseline
B
25
APD Range
(ms)
5
APD standard
deviation
Fig. 8. APD heterogeneity in VT/VF (⫹) and
VT/VF (⫺) hearts. A and B: average APD heterogeneity at baseline and following late challenge
with diamide in VT/VF (⫺) and VT/VF (⫹)
hearts. Hearts that exhibited sustained VT/VF
within 30 min of diamide perfusion were considered VT/VF (⫹), whereas those that did not exhibit sustained VT/VF during the same time period were considered VT/VF(⫺). In VT/VF (⫹)
hearts, APD heterogeneity was computed during
the final minute of successful pacing before arrhythmia onset. In VT/VF (⫺) hearts, APD heterogeneity was computed at the end of the 30-min
diamide protocol.
in these hearts. In support of this hypothesis, Slodzinski et al.
(43) used two-photon microscopy to demonstrate that acute OS
by GSH oxidation readily produces heterogeneous fluctuations
in the mitochondrial ⌬⌿m and reactive oxygen species levels
between neighboring myocytes within the intact guinea pig
heart (43). Since ⌬⌿m oscillations can drive APD oscillations
(1), spatiotemporal changes in ⌬⌿m may indeed increase APD
heterogeneity across the heart. Moreover, we have recently
Diamide
(200µM)
20
VT/VF (-)
VT/VF (+)
P=0.01
15
10
5
0
Baseline
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
Diamide
(200µM)
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
found that increased ⌬⌿m heterogeneity is an important feature
of hypertrophied hearts, which are highly prone to arrhythmias
(22). Further studies are required to uncover the culprit molecular/metabolic mechanisms that underlie increased APD
heterogeneity in t1DM and to define their exact role in the
genesis of conduction block and arrhythmias.
In addition to APD heterogeneity, we also found that diamide promoted the formation of triggered beats in STZ hearts
(Fig. 6). Increased ventricular ectopy in the wake of a spatially
heterogeneous repolarizing substrate is consistent with enhanced sensitivity to arrhythmias. The striking finding of
diamide-mediated ectopy in STZ is consistent with increased
calcium sparks and triggered action potentials observed by
Zhou et al. (48) in guinea pig hearts during OS-induced
mitochondrial ⌬⌿m oscillations.
Finally, a major goal of our current study was to determine
whether restoration of blood glucose levels by insulin treatment reverse remodels the EP substrate, decreases the incidence of proarrhythmic triggers, and protects against arrhythmias in chronic hyperglycemia. Surprisingly, we found that
despite complete reversal of hyperglycemia (Fig. 2A), insulin
treatment failed to restore APD heterogeneity (Fig. 7) or to
suppress ASI (Fig. 6A). These findings indicate that chronic
remodeling in hyperglycemia likely involves complex signaling pathways which are not readily reversed by glucose control. Uncovering the signaling cascades that underlie EP remodeling will be essential for the prevention of arrhythmias in
t1DM. Our finding that diamide is an effective tool for unmasking arrhythmia propensity in STZ-injected animals suggests that enhancing the reactive oxygen species scavenging
capacity of myocytes may indeed be a powerful antiarrhythmic
strategy.
Limitations
Our study has several important limitations that require
mention. For one, this guinea pig model, which is not associated with weight loss, may not recapitulate key clinical features
of human t1DM. Despite achieving a similar percent rise in
plasma glucose levels as seen in patients with diabetes, we
were careful not to define this as a model of t1DM but rather
of chronic hyperglycemia. Moreover, important EP distinctions are known to exist between myocytes from guinea pigs
and humans, including presence of a major redox-sensitive
repolarizing current (Ito) in humans but not guinea pigs.
In our experiments, diamide was used as a prooxidant tool to
investigate differences in EP properties between groups under
stress conditions. Diamide was specifically chosen because of
the established role of GSH depletion in t1DM. It is important
to note, however, that ex vivo diamide perfusion is a highly
artificial stressor, and therefore caution must be exercised
when extrapolating our findings to in vivo OS associated with
clinically relevant diseases such as heart failure or ischemiareperfusion injury.
While our finding of increased APD heterogeneity in VT/VF
prone hearts suggests a reentrant mechanism, we did not map
the moment of initiation of these spontaneous arrhythmias.
Therefore, we cannot be certain that these arrhythmias were
initiated by reentrant circuits. Of note, optical mapping performed shortly following the initiation of arrhythmias consis-
H925
tently revealed the presence of wave breaks and reentrant
activity (not shown).
Finally, motion artifact was suppressed using electromechanical uncoupling with blebbistatin. Previous studies have
found minimal effects of this strategy on key EP properties and
arrhythmia propensity compared with other uncoupling agents
(15, 27). However, blebbistatin may theoretically alter the
response of hearts to diamide. By using an identical concentration of blebbistatin in all our experiments, we ensured that
EP differences between groups were not likely due to electromechanical suppression.
ACKNOWLEDGMENTS
This work was supported by National Heart, Lung, and Blood Institute
Grant R01-HL-091923-01 and grants from the American Heart Association
and the Irma T. Hirschl and Monique Weill Caullier Trusts.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
C.X., N.B., C.G.T., M.A.A., and J.K. performed experiments; C.X., N.B.,
C.G.T., and M.A.A. analyzed data; C.X. and M.A.A. prepared figures; C.X.,
N.B., C.G.T., M.A.A., N.P., J.K., and F.G.A. approved final version of
manuscript; M.A.A., N.P., and F.G.A. edited and revised manuscript; F.G.A.
conception and design of research; F.G.A. interpreted results of experiments;
F.G.A. drafted manuscript.
REFERENCES
1. Akar FG, Aon MA, Tomaselli GF, O’Rourke B. The mitochondrial
origin of postischemic arrhythmias. J Clin Invest 115: 3527–3535, 2005.
2. Akar FG, O’Rourke B. Mitochondria are sources of metabolic sink and
arrhythmias. Pharmacol Ther 131: 287–294, 2011.
3. Akar FG, Rosenbaum DS. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res 93: 638 –645,
2003.
4. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms
underlying conduction slowing and arrhythmogenesis in nonischemic
dilated cardiomyopathy. Circ Res 95: 717–725, 2004.
5. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de
pointes in the long-QT syndrome. Circulation 105: 1247–1253, 2002.
6. Aomine M, Yamato T. Electrophysiological properties of ventricular
muscle obtained from spontaneously diabetic mice. Exp Anim 49: 23–33,
2000.
7. Biary N, Xie C, Kauffman J, Akar FG. Biophysical properties and
functional consequences of reactive oxygen species (ROS)-induced ROS
release in intact myocardium. J Physiol 589: 5167–5179, 2010.
8. Brindisi MC, Bouillet B, Verges B, Halimi S. Cardiovascular complications in type 1 diabetes mellitus. Diabetes Metab 36: 341–344, 2010.
9. Brown DA, Aon MA, Frasier CR, Sloan RC, Maloney AH, Anderson
EJ, O’Rourke B. Cardiac arrhythmias induced by glutathione oxidation
can be inhibited by preventing mitochondrial depolarization. J Mol Cell
Cardiol 48: 673–679, 2010.
10. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res
88: 229 –240, 2010.
11. Christensen TF, Tarnow L, Randlov J, Kristensen LE, Struijk JJ,
Eldrup E, Hejlesen OK. QT interval prolongation during spontaneous
episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate
correction. Diabetologia 53: 2036 –2041, 2010.
13. Ding Y, Zou R, Judd RL, Zhong J. Endothelin-1 receptor blockade
prevented the electrophysiological dysfunction in cardiac myocytes of
streptozotocin-induced diabetic rats. Endocrine 30: 121–127, 2006.
13a.Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at
onset and in early stages of type 1 diabetes in children and adolescents.
Diabetes Care 21: 1736 –1742, 1998.
14. Due-Andersen R, Hoi-Hansen T, Larroude CE, Olsen NV, Kanters
JK, Boomsma F, Pedersen-Bjergaard U, Thorsteinsson B. Cardiac
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.
H926
GSH OXIDATION AND ARRHYTHMIAS IN HYPERGLYCEMIA
repolarization during hypoglycaemia in type 1 diabetes: impact of basal
renin-angiotensin system activity. Europace 10: 860 –867, 2008.
15. Fedorov VV, Lozinsky IT, Sosunov EA, Anyukhovsky EP, Rosen MR,
Balke CW, Efimov IR. Application of blebbistatin as an excitationcontraction uncoupler for electrophysiologic study of rat and rabbit hearts.
Heart Rhythm 4: 619 –626, 2007.
16. Ghaly H, Boyle P, Vigmond E, Nygren A. Reduced conduction reserve
of the propagating cardiac impulse in the diabetic rat heart: a model study.
Conf Proc IEEE Eng Med Biol Soc 2008: 5926 –5929, 2008.
17. Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller
JH, Veglio M, Cavallo-Perin P. Incidence and risk factors of prolonged
QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 30: 2057–2063, 2007.
18. Glukhov AV, Fedorov VV, Kalish PW, Ravikumar VK, Lou Q, Janks
D, Schuessler RB, Moazami N, Efimov IR. Conduction remodeling in
human end-stage nonischemic left ventricular cardiomyopathy. Circulation 125: 1835–1847, 2010.
19. Howarth FC, Chandler NJ, Kharche S, Tellez JO, Greener ID,
Yamanushi TT, Billeter R, Boyett MR, Zhang H, Dobrzynski H.
Effects of streptozotocin-induced diabetes on connexin43 mRNA and
protein expression in ventricular muscle. Mol Cell Biochem 319: 105–114,
2008.
20. Howarth FC, Jacobson M, Qureshi MA, Shafiullah M, Hameed RS,
Zilahi E, Al Haj A, Nowotny N, Adeghate E. Altered gene expression
may underlie prolonged duration of the QT interval and ventricular action
potential in streptozotocin-induced diabetic rat heart. Mol Cell Biochem
328: 57–65, 2009.
21. Jin H, Chemaly ER, Lee A, Kho C, Hadri L, Hajjar RJ, Akar FG.
Mechanoelectrical remodeling and arrhythmias during progression of
hypertrophy. FASEB J 24: 451–463, 2010.
22. Jin H, Nass RD, Joudrey PJ, Lyon AR, Chemaly ER, Rapti K, Akar
FG. Altered spatiotemporal dynamics of the mitochondrial membrane
potential in the hypertrophied heart. Biophys J 98: 2063–2071, 2010.
23. Kleber AG, Janse MJ, Wilms-Schopmann FJ, Wilde AA, Coronel R.
Changes in conduction velocity during acute ischemia in ventricular
myocardium of the isolated porcine heart. Circulation 73: 189 –198, 1986.
24. Kuppermann N, Park J, Glatter K, Marcin JP, Glaser NS. Prolonged
QT interval corrected for heart rate during diabetic ketoacidosis in children. Arch Pediatr Adolesc Med 162: 544 –549, 2008.
25. Lengyel C, Virag L, Biro T, Jost N, Magyar J, Biliczki P, Kocsis E,
Skoumal R, Nanasi PP, Toth M, Kecskemeti V, Papp JG, Varro A.
Diabetes mellitus attenuates the repolarization reserve in mammalian
heart. Cardiovasc Res 73: 512–520, 2007.
25a.Li S, Li X, Li YL, Shao CH, Bidasee KR, Rozanski GJ. Insulin
regulation of glutathione and contractile phenotype in diabetic rat ventricular myocytes. Am J Physiol Heart Circ Physiol 292: H1619 –H1629,
2007.
26. Li X, Xu Z, Li S, Rozanski GJ. Redox regulation of Ito remodeling in
diabetic rat heart. Am J Physiol Heart Circ Physiol 288: H1417–H1424,
2005.
27. Lou Q, Li W, Efimov IR. The role of dynamic instability and wavelength
in arrhythmia maintenance as revealed by panoramic imaging with blebbistatin vs. 2,3-butanedione monoxime. Am J Physiol Heart Circ Physiol
302: H262–H269, 2012.
28. Lyon AR, Joudrey PJ, Jin D, Nass RD, Aon MA, O’Rourke B, Akar
FG. Optical imaging of mitochondrial function uncovers actively propagating waves of mitochondrial membrane potential collapse across intact
heart. J Mol Cell Cardiol 49: 565–575, 2010.
29. McNally PG, Lawrence IG, Panerai RB, Weston PJ, Thurston H.
Sudden death in type 1 diabetes. Diabetes Obes Metab 1: 151–158, 1999.
31. Nishiyama A, Ishii DN, Backx PH, Pulford BE, Birks BR, Tamkun
MM. Altered K⫹ channel gene expression in diabetic rat ventricle:
isoform switching between Kv42 and Kv14. Am J Physiol Heart Circ
Physiol 281: H1800 –H1807, 2001.
32. Nygren A, Olson ML, Chen KY, Emmett T, Kargacin G, Shimoni Y.
Propagation of the cardiac impulse in the diabetic rat heart: reduced
conduction reserve. J Physiol 580: 543–560, 2007.
33. Pacher P, Ungvari Z, Nanasi PP, Kecskemeti V. Electrophysiological
changes in rat ventricular and atrial myocardium at different stages of
experimental diabetes. Acta Physiol Scand 166: 7–13, 1999.
34. Pastore A, Ciampalini P, Tozzi G, Pecorelli L, Passarelli C, Bertini E,
Piemonte F. All glutathione forms are depleted in blood of obese and type
1 diabetic children. Pediatr Diabetes 13: 272–277. 2010.
35. Poelzing S, Rosenbaum DS. Altered connexin43 expression produces
arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 287:
H1762–H1770, 2004.
36. Raimondi L, De Paoli P, Mannucci E, Lonardo G, Sartiani L,
Banchelli G, Pirisino R, Mugelli A, Cerbai E. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic
rats. Diabetes 53: 1927–1933, 2004.
37. Robillon JF, Sadoul JL, Benmerabet S, Joly-Lemoine L, Fredenrich
A, Canivet B. Assessment of cardiac arrhythmic risk in diabetic patients
using QT dispersion abnormalities. Diabetes Metab 25: 419 –423, 1999.
38. Schlosser MJ, Kapeghian JC, Verlangieri AJ. Effects of streptozotocin
in the male guinea pig: a potential animal model for studying diabetes. Life
Sci 35: 649 –655, 1984.
39. Shimoni Y, Emmett T, Schmidt R, Nygren A, Kargacin G. Sexdependent impairment of cardiac action potential conduction in type 1
diabetic rats. Am J Physiol Heart Circ Physiol 296: H1442–H1450, 2009.
40. Shimoni Y, Ewart HS, Severson D. Type I and II models of diabetes
produce different modifications of K⫹ currents in rat heart: role of insulin.
J Physiol 507: 485–496, 1998.
41. Shimoni Y, Firek L, Severson D, Giles W. Short-term diabetes alters K⫹
currents in rat ventricular myocytes. Circ Res 74: 620 –628, 1994.
42. Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from
molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12: 537–577, 2010.
43. Slodzinski MK, Aon MA, O’Rourke B. Glutathione oxidation as a
trigger of mitochondrial depolarization and oscillation in intact hearts. J
Mol Cell Cardiol 45: 650 –660, 2008.
44. Ursell PC, Gardner PI, Albala A, Fenoglio JJ Jr, Wit AL. Structural
and electrophysiological changes in the epicardial border zone of canine
myocardial infarcts during infarct healing. Circ Res 56: 436 –451, 1985.
45. Xu Z, Patel KP, Lou MF, Rozanski GJ. Up-regulation of K⫹ channels
in diabetic rat ventricular myocytes by insulin and glutathione. Cardiovasc
Res 53: 80 –88, 2002.
46. Yuill KH, Tosh D, Hancox JC. Streptozotocin-induced diabetes modulates action potentials and ion channel currents from the rat atrioventricular node. Exp Physiol 95: 508 –517, 2010.
47. Zhang Y, Xiao J, Lin H, Luo X, Wang H, Bai Y, Wang J, Zhang H,
Yang B, Wang Z. Ionic mechanisms underlying abnormal QT prolongation and the associated arrhythmias in diabetic rabbits: a role of rapid
delayed rectifier K⫹ current. Cell Physiol Biochem 19: 225–238, 2007.
48. Zhou L, Aon MA, Liu T, O’Rourke B. Dynamic modulation of Ca2⫹
sparks by mitochondrial oscillations in isolated guinea pig cardiomyocytes
under oxidative stress. J Mol Cell Cardiol 51: 632–639, 2010.
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00026.2012 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (003.238.182.043) on February 18, 2022.